As Mediclinic is primarily listed on the London Stock Exchange, with secondary listings on the Johannesburg Stock Exchange and Namibian Stock Exchange, the transaction is governed by English law, but its cross-border nature requires complex alignment with the listings requirements in all three countries. 

Given the expected flow of foreign exchange into South Africa from the deal, it also required exchange control approval from the Financial Surveillance Department of the South African Reserve Bank. 

The transaction is also classified as a large merger in South Africa, and our team has supported the client with extensive engagement with the Competition Commission as well as the Department of Trade, Industry and Competition, particularly around the public interest assessment.